Chemotherapy for Advanced Gastric Cancer
Author Information
Author(s): Kornek G V, Raderer M, Schüll B, Fiebiger W, Gedlicka C, Lenauer A, Depisch D, Schneeweiss B, Lang F, Scheithauer W
Primary Institution: University Vienna
Hypothesis
The study aims to evaluate the antitumour activity and tolerance of paclitaxel plus cisplatin in chemotherapy-naive patients with disseminated gastric cancer.
Conclusion
The combination of paclitaxel and cisplatin shows promising therapeutic activity in patients with advanced gastric cancer.
Supporting Evidence
- The overall response rate was 44%, with 11% complete remissions.
- The median survival time was 11.2 months.
- Haematologic toxicity was common, but severe cases were limited.
Takeaway
Doctors tested a new medicine for stomach cancer and found it helped many patients feel better and live longer.
Methodology
A phase II trial with 45 patients receiving biweekly chemotherapy of paclitaxel and cisplatin, with additional support from G-CSF and erythropoietin as needed.
Potential Biases
Potential biases due to the non-randomized nature of the study.
Limitations
The study design was non-randomized, limiting direct comparisons with other regimens.
Participant Demographics
Median age of participants was 59 years, with 13 females and 32 males.
Statistical Information
P-Value
0.05
Confidence Interval
29.7 to 60.0%
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website